Lupus & antiphospholipid syndrome
Predictors of Mortality in Antiphospholipid Antibody–Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository
Authors' conclusion
In our cohort of persistently aPL-positive patients, the mortality rate was 5% after a median follow-up of five years and was highest for patients ≥60 years old at registry entry. History of arterial thrombosis, concomitant SAIDs, and baseline any CVD risk factor independently predicted future death.
Study context
- Population
- Persistently aPL-positive patients with and without antiphospholipid syndrome (APS) classification, APS ACTION registry
- Participants
- 967 patients
- Exposure
- Deceased vs living aPL-positive patients; predictors of death
- Outcome
- Mortality rate, causes and predictors of death
Methodological detailsmulticentre, international registry, adjusted Cox proportional hazards model, Kaplan-Meier
- Multicentre
- International registry
- Adjusted Cox proportional hazards model
- Kaplan-Meier
Main finding
As reported in the abstract
Deceased
43
5%
Arterial thrombosis, HR
2.94 (1.50-5.76) (95% CI)
Concomitant systemic autoimmune diseases (SAIDs), HR
2.97 (1.56-5.63) (95% CI)
Baseline any cardiovascular disease (CVD) risk factor, HR
2.43 (1.05-5.71) (95% CI)
Observational data: associations, not effects.
Further findings
Mortality by age at registry entry
- Mortality highest for patients ≥60 years old at registry entry
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →